US 12,303,511 B2
Methods related to opioid therapeutics
Kirill Martemyanov, Jupiter, FL (US); and Brock Grill, Lake Worth, FL (US)
Assigned to University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Filed by University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Filed on Jun. 12, 2024, as Appl. No. 18/740,610.
Application 18/740,610 is a division of application No. 17/286,187, granted, now 12,042,496, previously published as PCT/US2019/056284, filed on Oct. 15, 2019.
Claims priority of provisional application 62/746,343, filed on Oct. 16, 2018.
Prior Publication US 2024/0342180 A1, Oct. 17, 2024
Int. Cl. A61K 31/519 (2006.01); A61K 31/095 (2006.01); A61K 31/166 (2006.01); A61K 31/175 (2006.01); A61K 31/397 (2006.01); A61P 25/36 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/095 (2013.01); A61K 31/166 (2013.01); A61K 31/175 (2013.01); A61K 31/397 (2013.01); A61P 25/36 (2018.01)] 10 Claims
OG exemplary drawing
 
1. A method for suppressing or ameliorating withdrawal symptoms in subjects with chronic use of an opioid drug, comprising administering to the subject a pharmaceutical composition comprising an effective amount of a compound that down-regulates expression or cellular activity of GPR139 or an ortholog thereof, wherein the compound is a small organic molecule, thereby suppressing or ameliorating withdrawal symptoms in the subject.